Stock listing
NASDAQ:CLNN Clene Inc. Stock
Home listing (NASDAQ) of Clene Inc.
Follow Clene Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CLNN
$3.52 USD +0.10 (+2.9%)
Close on Nov 20, 2026
- Day range
- $3.30 – $3.60 USDNov 20, 2026
- Volume
- 143,565 sharesNov 20, 2026
- Market cap
- $50.69M USDAt the close on Nov 20, 2026 · price × 14.40M shares outstanding
- 52-week range
- $3.02 – $10.84 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $436,932 USDMedian day 107,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CLNN · Home | $3.52 USD | +0.10 (+2.9%) | 143,565 | $3.41 | $3.60 | $3.30 | $3.42 | Close on Nov 20, 2026 |
| Frankfurt:84C0 | €3.10 EUR | +0.06 (+2.0%) | — | €3.10 | €3.10 | €3.10 | €3.04 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CLNN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.52 | +0.10 | +2.9% | $3.41 | $3.60 | $3.30 | 143,565 | |
| $3.42 | +0.20 | +6.2% | $3.23 | $3.59 | $3.10 | 239,332 | |
| $3.22 | -0.44 | -12.0% | $3.71 | $3.71 | $3.105 | 204,947 | |
| $3.66 | -0.26 | -6.6% | $3.86 | $3.92 | $3.54 | 123,344 | |
| $3.92 | -0.08 | -2.0% | $4.43 | $4.43 | $3.86 | 28,739 | |
| $4.00 | -0.195 | -4.6% | $4.16 | $4.25 | $3.92 | 109,045 | |
| $4.195 | -0.215 | -4.9% | $4.38 | $4.566 | $4.17 | 208,437 | |
| $4.41 | +0.03 | +0.7% | $4.40 | $4.81 | $4.38 | 145,314 | |
| $4.38 | +0.43 | +10.9% | $3.97 | $4.93 | $3.97 | 201,466 | |
| $3.95 | -0.02 | -0.5% | $3.96 | $4.11 | $3.755 | 60,703 | |
| $3.97 | -0.13 | -3.2% | $4.04 | $4.24 | $3.675 | 116,944 | |
| $4.10 | +0.33 | +8.8% | $3.93 | $4.24 | $3.805 | 114,945 | |
| $3.77 | +0.16 | +4.4% | $3.65 | $3.90 | $3.65 | 44,308 | |
| $3.61 | -0.22 | -5.7% | $3.85 | $3.925 | $3.605 | 54,013 | |
| $3.83 | -0.07 | -1.8% | $3.75 | $3.95 | $3.75 | 47,081 | |
| $3.90 | -0.13 | -3.2% | $3.97 | $3.99 | $3.87 | 34,114 | |
| $4.03 | +0.06 | +1.5% | $3.96 | $4.05 | $3.90 | 43,856 | |
| $3.97 | +0.13 | +3.4% | $3.84 | $3.99 | $3.84 | 31,272 | |
| $3.84 | -0.04 | -1.0% | $3.92 | $3.92 | $3.78 | 33,858 | |
| $3.88 | 0.00 | 0.0% | $3.79 | $3.97 | $3.77 | 21,396 | |
| $3.88 | +0.12 | +3.2% | $3.73 | $4.01 | $3.63 | 124,247 | |
| $3.76 | +0.03 | +0.8% | $3.76 | $4.00 | $3.71 | 84,562 | |
| $3.73 | +0.44 | +13.4% | $3.52 | $4.05 | $3.196 | 202,009 | |
| $3.29 | +0.19 | +6.1% | $3.30 | $3.391 | $3.10 | 88,490 | |
| $3.10 | -0.21 | -6.3% | $3.39 | $3.39 | $3.02 | 204,400 | |
| $3.31 | 0.00 | 0.0% | $3.25 | $3.44 | $3.20 | 134,000 | |
| $3.31 | -0.08 | -2.4% | $3.38 | $3.40 | $3.24 | 71,400 | |
| $3.39 | -0.29 | -7.9% | $3.69 | $3.70 | $3.36 | 114,700 | |
| $3.68 | -0.18 | -4.7% | $3.93 | $3.93 | $3.67 | 73,700 | |
| $3.86 | -0.02 | -0.5% | $3.83 | $3.96 | $3.80 | 48,100 | |
| $3.88 | -0.04 | -1.0% | $3.94 | $3.96 | $3.77 | 82,300 | |
| $3.92 | +0.05 | +1.3% | $3.85 | $4.01 | $3.71 | 40,500 | |
| $3.87 | -0.04 | -1.0% | $3.92 | $4.04 | $3.80 | 45,000 | |
| $3.91 | -0.17 | -4.2% | $4.09 | $4.11 | $3.80 | 278,200 | |
| $4.08 | +0.06 | +1.5% | $4.08 | $4.17 | $3.97 | 61,500 | |
| $4.02 | -0.06 | -1.5% | $4.10 | $4.15 | $4.00 | 100,000 | |
| $4.08 | -0.02 | -0.5% | $4.14 | $4.33 | $4.01 | 51,800 | |
| $4.10 | +0.04 | +1.0% | $4.10 | $4.26 | $4.06 | 70,400 | |
| $4.06 | -0.24 | -5.6% | $4.24 | $4.37 | $4.01 | 91,700 | |
| $4.30 | +0.09 | +2.1% | $4.15 | $4.49 | $4.12 | 136,400 | |
| $4.21 | -0.08 | -1.9% | $4.27 | $4.38 | $4.09 | 47,700 | |
| $4.29 | -0.09 | -2.1% | $4.36 | $4.44 | $4.15 | 75,200 | |
| $4.38 | -0.16 | -3.5% | $4.51 | $4.70 | $4.27 | 135,800 | |
| $4.54 | +0.19 | +4.4% | $4.40 | $4.70 | $4.40 | 108,900 | |
| $4.35 | +0.20 | +4.8% | $4.16 | $4.44 | $4.05 | 191,400 | |
| $4.15 | +0.29 | +7.5% | $3.86 | $4.23 | $3.81 | 138,800 | |
| $3.86 | -0.16 | -4.0% | $4.05 | $4.37 | $3.84 | 255,800 | |
| $4.02 | +0.74 | +22.6% | $3.25 | $4.18 | $3.25 | 478,800 | |
| $3.28 | -0.29 | -8.1% | $3.57 | $3.72 | $3.26 | 140,900 | |
| $3.57 | -0.08 | -2.2% | $3.72 | $3.76 | $3.52 | 125,000 | |
| $3.65 | -0.07 | -1.9% | $3.67 | $3.93 | $3.61 | 113,000 | |
| $3.72 | +0.10 | +2.8% | $3.67 | $3.84 | $3.48 | 159,300 | |
| $3.62 | -0.23 | -6.0% | $3.82 | $3.82 | $3.60 | 252,600 | |
| $3.85 | -0.15 | -3.7% | $3.92 | $4.00 | $3.72 | 122,600 | |
| $4.00 | -0.16 | -3.8% | $4.18 | $4.22 | $3.75 | 145,000 | |
| $4.16 | +0.05 | +1.2% | $4.10 | $4.28 | $3.88 | 107,600 | |
| $4.11 | -0.17 | -4.0% | $4.22 | $4.42 | $4.02 | 159,100 | |
| $4.28 | +0.05 | +1.2% | $4.31 | $4.32 | $4.11 | 41,300 | |
| $4.23 | -0.24 | -5.4% | $4.43 | $4.74 | $4.17 | 59,700 | |
| $4.47 | -0.18 | -3.9% | $4.67 | $4.80 | $4.40 | 33,000 | |
| $4.65 | +0.21 | +4.7% | $4.43 | $4.75 | $4.26 | 89,900 | |
| $4.44 | +0.005 | +0.1% | $4.47 | $4.58 | $4.20 | 112,100 | |
| $4.435 | +0.115 | +2.7% | $4.31 | $4.53 | $4.24 | 37,313 | |
| $4.32 | -0.05 | -1.1% | $4.40 | $4.41 | $4.13 | 28,900 | |
| $4.37 | +0.18 | +4.3% | $4.24 | $4.37 | $4.10 | 23,100 |
Splits
1 split · NASDAQ:CLNN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:CLNN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights
Latest deck · Aug 10, 2026
Investor Presentation (August 2026)
Investor deck · 25 slides
Latest news
Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights
Nov 4, 2026
Closed $4.10 (+8.8%) on Nov 4, 2026
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
Oct 19, 2026
Closed $3.29 (+6.1%) on Oct 19, 2026
Clene to Present at Upcoming Investor Conferences
Sep 22, 2026
Closed $4.38 (-3.5%) on Sep 22, 2026
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
Sep 21, 2026
Closed $4.54 (+4.4%) on Sep 21, 2026
Clene Announces $4 Million Registered Direct Offering
Sep 15, 2026
Closed $4.02 (+22.6%) on Sep 15, 2026
Clene to Present at Upcoming September Investor Conferences
Sep 3, 2026
Closed $4.00 (-3.8%) on Sep 3, 2026
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
Aug 14, 2026
Closed $4.14 (-1.2%) on Aug 14, 2026
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
Aug 10, 2026
Closed $5.16 (-2.3%) on Aug 10, 2026
Clene to Present at The Canaccord 46th Annual Growth Conference
Jul 29, 2026
Closed $4.72 (-5.4%) on Jul 29, 2026
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
May 14, 2026
Closed $7.05 (+8.5%) on May 14, 2026
Clene Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 126 in all · newest Nov 4, 2026 · oldest 2021
- Decks
- 44 decks · latest Aug 10, 2026
Where Clene Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CLNN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CLNN | BOATS | United States | USD |
| Frankfurt:84C0 | Frankfurt | Germany | EUR |
| Tradegate:84C0 | Tradegate | Germany | EUR |
Valuation
EV/sales 245× against a median of 5.9×: 5th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $58.31M USD
- P/E
- Loss
- EV/sales
- 245×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- −80.7%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.48
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Clene Inc. · NASDAQ:CLNN | US$50.69M | US$58.31M | n/a | 245× | n/a | n/a | n/a | n/a | 1.48 |
| Impact BioMedical, Inc. · AMEX:IBO | US$53.31M | US$53.29M | 33.0× | 1,402× | n/a | 5.3× | n/a | 0.0× | 0.06 |
| XBiotech Inc. · NASDAQ:XBIT | US$52.74M | −US$52.29M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 0.52 |
| Bonus Biogroup Ltd. · TASE:BONS | US$52.22M | US$54.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| iBio, Inc. · NASDAQ:IBIO | US$51.45M | −US$23.13M | n/a | −21.5× | n/a | 0.7× | n/a | 0.0× | 2.01 |
| Sirnaomics Ltd. · HKEX:2257 | US$51.13M | US$69.20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cinclus Pharma Holding AB · OMXSTO:CINPHA | US$51.07M | US$13.13M | n/a | 3.8× | n/a | 2.6× | −765.8% | 0.0× | n/a |
| Aldeyra Therapeutics, Inc. · NASDAQ:ALDX | US$50.70M | US$9.72M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 0.66 |
| Aptamer Sciences, Inc. · KRX:291650 | US$49.50M | US$34.66M | n/a | 8.6× | n/a | 1.6× | −215.8% | 0.0× | n/a |
| Acrivon Therapeutics, Inc. · NASDAQ:ACRV | US$49.35M | −US$26.60M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.09 |
| SYNTHAVERSE Spolka Akcyjna · GPW:SVE | US$48.68M | US$70.98M | n/a | 5.9× | n/a | 1.7× | −43.1% | 0.8× | n/a |
| Median of the others | US$51.10M | US$23.90M | 33.0× | 5.9× | 1.5× | −215.8% | 0.0× | 0.66 |
Forecasts
4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 32.20 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.62 · 2 analysts
- Revenue, year to Dec 2026
- 188.3K · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Rob Etherington | President & CEO |
| Morgan Brown | Chief Financial Officer |
| Jerry Miraglia | General Counsel and Corporate Secretary |
| Adam Dorfman | Vice President, Quality & Technical Operations |
| Austin Rynders | Vice President, Clinical Operations |
| D. Kyle Pierce | Vice President, Research & Development |
| Benjamin Greenberg | Head of Medical |
| Joanne Zhongyan Zhang M.D. | Director of Micro and Biology |
| Mark Mortenson | Chief Science Officer |
| Mary Anne McNeil | Head of Human Resources |
| Michael Hotchkin | Chief Development Officer |
| Rowena Green | Executive Director, Quality Assurance |
Board
| Director | Role |
|---|---|
| David J. Matlin | Chairman |
| Alison H. Mosca | Board Member |
| Arjun JJ Desai | Board Member |
| Jonathon T. Gay | Board Member |
| Matthew Kiernan | Board Member |
| Reed N. Wilcox | Board Member |
| Rob Etherington | President & CEO |
| Rowena Green | Executive Director, Quality Assurance |
| Shalom Jacobovitz | Board Member |
| Vallerie V. McLaughlin | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | +8.8% |
| Q2 2026 | Aug 14, 2026 · Before open | −1.2% |
| Q1 2026 | May 14, 2026 · Before open | +8.5% |
| Q4 2025 | Mar 12, 2026 | +2.5% |
| Q3 2025 | Nov 13, 2025 · Before open | −22.4% |
| Q2 2025 | Aug 14, 2025 · Before open | −1.4% |
| Q1 2025 | May 7, 2025 · Before open | −10.5% |
| Q4 2024 | Mar 11, 2025 · Before open | +3.2% |
| Q3 2024 | Nov 13, 2024 · Before open | −9.1% |
| Q2 2024 | Aug 7, 2024 · Before open | −23.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | −0.4% |
| Q4 2023 | Mar 13, 2024 · Before open | −1.0% |
| Q3 2023 | Nov 7, 2023 · Before open | +8.0% |
| Q2 2023 | Aug 14, 2023 · Before open | +1.3% |
| Q1 2023 | May 12, 2023 · After close | +1.7% |
| Q4 2022 | Mar 13, 2023 · Before open | +7.9% |
| Q3 2022 | Nov 7, 2022 · Before open | −12.7% |
| Q2 2022 | Aug 15, 2022 · Before open | +5.8% |
| Q1 2022 | May 9, 2022 · Before open | −13.5% |
| Q4 2021 | Mar 11, 2022 · Before open | −3.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 25 slides | Aug 10, 2026 |
| Corporate Update (October 2025) | Corporate update | 32 slides | Oct 14, 2025 |
| Investor Presentation (November 2024) | Investor deck | 30 slides | Nov 13, 2024 |
| Investor Presentation (August 2024) | Investor deck | 38 slides | Aug 6, 2024 |
| Technical Presentation (April 2024) | Technical | 10 slides | Apr 16, 2024 |
| Technical Presentation (February 2024) | Technical | 13 slides | Feb 22, 2024 |
| Investor Presentation (January 2024) | Investor deck | 34 slides | Jan 8, 2024 |
| AAN 2024 | Conference | 10 slides | 2024 |
| Investor Presentation (December 2023) | Investor deck | 32 slides | Dec 21, 2023 |
| Corporate Update (November 2023) | Corporate update | 29 slides | Nov 7, 2023 |
All 44 decks
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock Closed: US$4M raised · US$3.28 a share Buyers: David Matlin (Led the offering); Kensington Capital Holdings Insiders: Led by the Chairman of the Board, David Matlin, alongside the Chief Executive Officer and other existing shareholders including insiders Use of proceeds: Fund operations through mid-first quarter 2027, beyond the potential FDA decision on accepting the CNM-Au8 NDA for review | Sep 21, 2026 |
| Registered direct offering of common stock Announced: about US$7M · US$7 a share · Canaccord Genuity LLC Dealers: Canaccord Genuity LLC (lead) Use of proceeds: General corporate purposes, NDA filing for CNM-Au8, expanded access and Phase 3 trial, manufacturing expansion, commercialization and early-stage R&D | May 5, 2026 |
| Registered direct offering of common stock with Series A and Series B warrants Announced: about US$28M · US$6.5 a share · Warrants at US$6 · BTIG, LLC Dealers: BTIG, LLC (lead) Buyers: Boxer Capital; Coastlands Capital; Vivo Capital Insiders: Offering priced above market to new, existing and insider investors, including other current insider investors Use of proceeds: Fund operations through potential FDA NDA acceptance and approval and commercialization of CNM-Au8 in ALS | Jan 9, 2026 |
| Not stated Closed: US$1.2M raised Use of proceeds: Fund operations into the second quarter of 2026 | Nov 13, 2025 |
| Equity Closed: US$1.9M raised Use of proceeds: To fund operations into the first quarter of 2026 | Aug 14, 2025 |
| Convertible debt facility Made bigger: US$1.5M Use of proceeds: To fund operations into the first quarter of 2026 | Aug 14, 2025 |
| Secured, partially convertible note Announced: US$10M Insiders: The note was signed with three entities, all of which are affiliated with Clene Use of proceeds: Repay the remaining Avenue Capital senior loan and extend cash runway to generate data for the CNM-Au8 ALS drug application | Dec 19, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200.0K | 342.0K | 654.0K | 473.0K | 723.0K | 206.0K | 0 | ||
| Cost of revenue | 43.0K | 70.0K | 121.0K | 26.0K | 289.0K | 65.0K | 900.0K | ||
| Gross profit | 157.0K | 272.0K | 533.0K | 447.0K | 434.0K | 141.0K | -900.0K | ||
| Research and development | 14.0M | 20.1M | 26.7M | 31.9M | 28.4M | 15.2M | 9.56M | 6.64M | |
| Selling, general and administrative | 9.23M | 13.3M | 14.4M | 16.2M | 18.8M | 3.26M | 6.77M | 2.52M | |
| Operating income | -23.1M | -33.1M | -40.5M | -48.4M | -50.0M | -20.2M | -16.3M | -323.9K | -2.39K |
| Depreciation and amortization | 1.50M | 1.65M | 1.71M | 1.02M | 955.0K | 963.0K | 848.0K | 672.0K | |
| EBITDA | -21.6M | -31.4M | -38.8M | -47.4M | -49.0M | -19.3M | -15.5M | 348.1K | |
| Interest expense | 2.68M | 4.06M | 4.56M | 3.30M | 870.0K | 950.0K | 88.0K | 0 | |
| Income before tax | -26.2M | -39.4M | -49.5M | -29.9M | -10.2M | -18.9M | -16.2M | 19.4K | -2.39K |
| Income tax | 0 | 0 | 0 | 0 | -428.0K | 406.0K | 115.0K | -375.3K | |
| Net income | -26.2M | -39.4M | -49.5M | -29.9M | -9.74M | -19.3M | -16.2M | -277.3K | -2.39K |
| Earnings per share, basic | -2.65 | -5.67 | -9.43 | -0.46 | -0.16 | -1.10 | -0.93 | -0.09 | -0.00 |
| Earnings per share, diluted | -0.16 | -1.10 | -0.93 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.19M | 12.2M | 28.8M | 18.3M | 50.3M | 59.3M | 8.79M | 743.8K | |
| Short-term investments | 0 | 6.18M | 4.98M | 0 | |||||
| Receivables | 0 | 64.0K | 143.0K | 189.0K | 49.0K | 21.0K | 604.0K | ||
| Inventory | 37.0K | 68.0K | 37.0K | 43.0K | 41.0K | 191.0K | 28.0K | ||
| Current assets | 8.98M | 16.2M | 38.9M | 29.2M | 54.6M | 63.0M | 9.48M | 790.5K | |
| Property, plant and equipment | 15.2M | 5.17M | 4.22M | 4.32M | 4.47M | ||||
| Total assets | 18.1M | 27.3M | 52.3M | 44.5M | 63.1M | 68.2M | 14.9M | 47.2M | |
| Accounts payable | 892.0K | 1.24M | 1.50M | 3.01M | 1.92M | 1.12M | 889.0K | 1.10M | |
| Current liabilities | 10.8M | 10.3M | 25.3M | 13.9M | 6.03M | 11.7M | 4.31M | 222.2K | |
| Long-term debt | 13.5M | 15.4M | 7.15M | 19.3M | 14.5M | 1.95M | 640.0K | ||
| Total debt | 17.8M | 20.8M | 32.2M | 31.8M | 24.0M | 5.92M | 2.88M | 3.22M | |
| Total liabilities | 35.7M | 36.2M | 39.0M | 41.3M | 50.5M | 67.9M | 9.99M | 42.2M | |
| Shareholders' equity | -17.6M | -8.86M | 13.4M | 3.24M | 12.6M | 341.0K | -67.8M | 5.00M | |
| Shares outstanding | 10.8M | 8.09M | 6.42M | 74.8M | 62.3M | 59.5M | 17.4M | 3.12M | 3.12M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -18.5M | -21.3M | -30.2M | -39.0M | -34.6M | -18.9M | -13.2M | -205.4K |
| Capital spending | -39.0K | -15.0K | -330.0K | -5.18M | -1.33M | -387.0K | -294.0K | -752.0K |
| Free cash flow | -18.6M | -21.3M | -30.5M | -44.2M | -36.0M | -19.3M | -13.5M | -957.4K |
| Cash from investing | -39.0K | 6.32M | -1.50M | -10.2M | -1.33M | -387.0K | -294.0K | -46.0M |
| Cash from financing | 11.5M | -1.53M | 42.2M | 17.2M | 27.1M | 69.5M | 5.50M | 46.9M |
| Share buybacks | 11.8M | 7.80M | 31.1M | |||||
| Change in cash | -6.97M | -16.7M | 10.5M | -32.0M | -8.93M | 50.5M | -7.99M | 787.8K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 19, 2026 | Material contract | SEC |
| 8-K · Current report | Oct 19, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Sep 16, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 5, 2026 | Offer document | SEC |
| SD · Specialized disclosure | May 22, 2026 | ESG report | SEC |
| 8-K · Current report | May 22, 2026 | Material contract | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 8-K · Current report | May 5, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 5, 2026 | Offer document | SEC |
| 424B5 · Prospectus | May 5, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 8-K · Current report | May 4, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 10, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 24, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2026 | Material contract | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| 8-K · Current report | Feb 24, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 9, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 25-NSE | Dec 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 3, 2025 | Current report | SEC |
| 8-K · Current report | Dec 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 17, 2025 | Current report | SEC |
| 424B5 · Prospectus | Oct 17, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 14, 2025 | Results | SEC |
| 4/A · Change in ownership, amended | Sep 30, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 30, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 15, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Sep 12, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 10, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 9, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 5, 2025 | Current report | SEC |
| 424B5 · Prospectus | Sep 5, 2025 | Offer document | SEC |
| S-3 · Registration statement | Sep 5, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Sep 5, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 3, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jul 3, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 8-K · Current report | May 23, 2025 | Management or board change | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| SD · Specialized disclosure | May 16, 2025 | ESG report | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| 424B5 · Prospectus | Apr 28, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 28, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 28, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 23, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 8, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 8, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 8, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 8, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 28, 2025 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Mar 27, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Mar 27, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 27, 2025 | Current report | SEC |
| 424B5 · Prospectus | Mar 24, 2025 | Offer document | SEC |
| S-3 · Registration statement | Mar 24, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 12, 2025 | Current report | SEC |
This page holds 200 of 716 filings. Open Filings
Cap table
Built by 6ix from Clene Inc.’s releases · as of Nov 2, 2026
- Common shares
- 14,400,175
- Fully diluted
- 14,400,175
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 14,400,175 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 14,400,175 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Morgan Brown Other companies: Lipocine Inc. (Chief Financial Officer · Sep 16, 2013 – Dec 7, 2021 · Past); World Heart Corp (Executive VP · Aug 10, 2009 – Sep 1, 2011 · Past); NPS Pharmaceuticals Inc (Vice President, Finance · Jan 17, 2006 – Oct 17, 2006 · Past) | Chief Financial Officer · Since at least Feb 1, 2022 |
| Arjun JJ Desai Other companies: Longeveron Inc. (Independent Director · Since at least Jul 2, 2026); TriSalus Life Sciences, Inc. (Director · Since at least Aug 10, 2023) | Board Member · Since at least Sep 18, 2023 |
| Adam Dorfman | Vice President, Quality & Technical Operations · Since at least Nov 4, 2026 |
| Alison H. Mosca | Director · Since at least Sep 16, 2026 |
| Austin Rynders | Vice President, Clinical Operations · Since at least Nov 4, 2026 |
| Benjamin Greenberg | Head of Medical · Since at least Sep 25, 2025 |
| David J. Matlin | Chairman · Since at least Sep 18, 2026 |
| D. Kyle Pierce | Vice President, Research & Development · Since at least Nov 4, 2026 |
| Fiona Costello | Director · Dec 30, 2020 – May 18, 2021 · Past |
| Jerry Miraglia | General Counsel and Corporate Secretary · Since at least Nov 4, 2026 |
All 22 people
| Person | Seat |
|---|---|
| Joanne Zhongyan Zhang M.D. | Director of Micro and Biology · Since at least Nov 4, 2026 |
| Jonathon T. Gay | Director · Since at least Dec 30, 2020 |
| Mark Mortenson | Chief Science Officer · Since at least Dec 30, 2020 |
| Mary Anne McNeil | Head of Human Resources · Since at least Nov 5, 2026 |
| Matthew Kiernan | Board Member · Since at least Nov 5, 2026 |
| Michael Hotchkin | Chief Development Officer · Since at least Dec 3, 2025 |
| Reed N. Wilcox | Board Member · Since at least Dec 30, 2020 |
| Robert Dee Etherington | President & CEO, Director · Since at least Sep 16, 2026 |
| Rob Etherington | President & CEO · Since at least Sep 18, 2026 |
| Rowena Green | Executive Director, Quality Assurance · Since at least Nov 5, 2026 |
| Shalom Jacobovitz | Board Member · Since at least Nov 5, 2026 |
| Vallerie V. McLaughlin | Director · Since at least Nov 28, 2023 |
Log in to ask 6ix AI your own questions about Clene Inc.